로딩 중…
지수 로딩 중…
HLB PHARMACEUTICAL CO., LTD.
047920· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩11,100+16.84%
2026-11-02
Financials
Valuation Metrics
HLB PHARMACEUTICAL CO., LTD.'s Market Cap is ₩4835B. At end of 2025 it was ₩6438B. Ranked #450 of 2,405 in KR market (top 19%), #161 of 1,627 on KOSDAQ (top 10%), #48 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 483.53B KRW | KR#450/2,405 Sec#48/231 |
| Revenue | 251.95B KRW | KR#912/2,405 Sec#48/231 |
| Net Income | 2.76B KRW | KR#1,361/2,405 Sec#96/231 |
| Total Assets | 178.03B KRW | KR#1,388/2,405 Sec#103/231 |
| Net Assets | 130.76B KRW | KR#1,226/2,405 Sec#93/231 |
| Employees | 207 | KR#1,071/2,405 Sec#90/231 |
| Value | ||
| P/E | 175.38x | KR#1,521/2,405 Sec#104/231 |
| P/B | 3.70x | KR#2,187/2,405 Sec#185/231 |
| P/S | 1.92x | KR#1,833/2,405 Sec#105/231 |
| EV/EBITDA | 264.12x | KR#1,536/2,405 Sec#107/231 |
| FCF Yield | -1.37% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 2.11% | KR#1,395/2,405 Sec#95/231 |
| ROA | 1.55% | KR#1,301/2,405 Sec#93/231 |
| Op. Margin | 0.74% | KR#1,526/2,405 Sec#107/231 |
| Revenue Growth | 68.61% | KR#140/2,405 Sec#22/231 |
| Earnings Growth | -50.86% | KR#1,055/2,405 Sec#71/231 |
| Financial Health | ||
| Debt Ratio | 36.15% | KR#709/2,405 Sec#87/231 |
| Total Debt | 15.00B KRW | KR#1,488/2,405 Sec#127/231 |
| FCF | -6.64B KRW | KR#1,568/2,405 Sec#127/231 |
| Cash | 4.51B KRW | KR#2,034/2,405 Sec#191/231 |
| Current Ratio | 1.88x | KR#922/2,405 Sec#104/231 |
| Net Debt/EBITDA | 5.61x | KR#1,064/2,405 Sec#78/231 |
| Performance | ||
| 1Y Return | -21.63% | KR#1,124/2,405 Sec#77/231 |
| 1M Return | 10.89% | KR#96/2,405 Sec#7/231 |
| From 52W High | -45.86% | KR#988/2,405 Sec#68/231 |
| 1Y MDD | -70.48% | KR#1,978/2,405 Sec#170/231 |
| Trading | ||
| Volume | 1,411,792 shares | KR#46/2,405 Sec#3/231 |
| Trading Value | 14.93B KRW | KR#148/2,405 Sec#8/231 |
| Foreign Own. | 0.00% | KR—/2,405 Sec—/231 |
| Per Share | ||
| EPS | 63 KRW | KR#1,485/2,405 Sec#103/231 |
| BPS | 3,002 KRW | KR#1,874/2,405 Sec#143/231 |
Company Info
동사는 1998년 씨트리로 설립되어 2020년 HLB그룹 편입과 함께 현 사명으로 변경함. 주요 사업은 전문의약품 제조·판매, 위수탁(CMO) 사업, 건강기능식품 판매이며, 로수듀오 등 160종 이상의 전문의약품을 위탁영업으로 판매하고 있음. 동탄 연구소 중심으로 주사제형 기반 신약 연구개발, 향남 신공장 신축으로 GMP 고도화, 시험 투자 확대로 경쟁력을 강화하고 있음. HLB제약는 1998년에 설립되었으며 경기도 남양주시에 본사를 두고 있습니다.